☆ 4.7 Article

The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study

JOURNAL OF CLINICAL MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

Ana Zabalza et al.

Summary: The study found that multiple sclerosis patients have similar incidence, risk factors, and outcomes for COVID-19 as the general population. Patients treated with anti-CD20 therapy for a longer period of time may be at a higher risk of COVID-19, and less than 20% generate an antibody response. Only age was related to severity.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Immunology

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab

Sridhar Chilimuri et al.

Summary: Vaccines play a crucial role in ending the COVID-19 pandemic, but their safety and efficacy in multiple sclerosis patients receiving immunosuppressive therapies is not well-documented. Patients on B cell depleting therapy like ocrelizumab show a weakened vaccine response.

VACCINES (2021)

Add to Collection

Article Clinical Neurology

Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases

Riccardo Nistri et al.

Summary: This study described a temporal association between COVID-19 vaccination and MS relapses in 16 patients, with 3 patients experiencing their first episode post-vaccination and 13 already diagnosed with MS. All relapses occurred 3 days to 3 weeks after vaccination, with evidence of radiological activity on MRI in all patients. The nature of this association, whether causal or incidental, remains to be determined.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

Anat Achiron et al.

Summary: The study shows that the COVID-19 BNT162b2 vaccine is safe for patients with MS, with no increased risk of relapse activity observed after vaccination.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel

Itay Lotan et al.

Summary: The study reported real-life safety data of the BNT162b2 COVID-19 vaccine in a cohort of MS patients. Most adverse events occurred within the first 24 hours after vaccination and resolved within 3 days, with the majority of patients not requiring medication for their symptoms. Further large-scale studies are needed to confirm these findings.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report

Giorgia T. Maniscalco et al.

Summary: A case of acute relapse in a woman with Multiple Sclerosis occurred shortly after mRNA COVID-19 vaccination, but the patient fully recovered from neurological symptoms after receiving methylprednisolone treatment. Further studies are needed to improve our understanding of the benefit/risk ratio of COVID-19 vaccines.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

Maria Pia Sormani et al.

Summary: This study found that anti-CD20 treatment and fingolimod in MS patients led to reduced humoral response to mRNA vaccines. mRNA-1273 vaccine resulted in significantly higher antibody levels compared to BNT162b2, suggesting it may be preferred for patients under certain treatments.

EBIOMEDICINE (2021)

Add to Collection

Article Neurosciences

Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study

Antonio Ziello et al.

Summary: The study results show that most MS patients accepted flu vaccination, emphasizing the importance of education and communication campaigns in improving vaccination rates. While the majority of patients were vaccinated, there is still room for improvement in increasing vaccination rates.

BRAIN SCIENCES (2021)

Add to Collection

Letter Health Care Sciences & Services

The epidemiological relevance of the COVID-19-vaccinated population is increasing

Gunter Kampf

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India

Chandramani Singh et al.

Summary: The case-control study conducted in Bihar, India, revealed that COVID-19 vaccines are effective in reducing the risk of SARS CoV-2 infection, lowering hospital stays, and decreasing the severity of the disease. The adjusted vaccine effectiveness for partial and full vaccination was estimated to be 52.0% and 83.0% respectively for preventing SARS CoV-2 infection. Sub-group analyses showed significantly lower hospital stays and disease severity among vaccinated individuals compared to unvaccinated.

EPIDEMIOLOGY AND INFECTION (2021)

Add to Collection

Review Pharmacology & Pharmacy

Current pharmacological treatments for COVID-19: What's next?

Cristina Scavone et al.

BRITISH JOURNAL OF PHARMACOLOGY (2020)

Add to Collection

Article Immunology

SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment

Di Mauro Gabriella et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?

Annalisa Capuano et al.

PHARMACOLOGICAL RESEARCH (2020)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Add to Collection

Article Clinical Neurology

Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis

Doriana Landi et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Chemistry, Medicinal

Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project

Giorgia Teresa Maniscalco et al.

PHARMACEUTICALS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy

Cristina Scavone et al.

EXPERT OPINION ON DRUG SAFETY (2019)

Add to Collection

Review Clinical Neurology

The role of infections in multiple sclerosis

Mariano Marrodan et al.

MULTIPLE SCLEROSIS JOURNAL (2019)

Add to Collection

Review Immunology

Sex differences in vaccine-induced humoral immunity

Stephanie Fischinger et al.

SEMINARS IN IMMUNOPATHOLOGY (2019)

Add to Collection

Review Clinical Neurology

Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010

Simon Faissner et al.

CNS DRUGS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Did the New Italian Law on Mandatory Vaccines Affect Adverse Event Following Immunization's Reporting? A Pharmacovigilance Study in Southern Italy

Cristina Scavone et al.

FRONTIERS IN PHARMACOLOGY (2018)

Add to Collection

Review Immunology

T Cell/B Cell Collaboration and Autoimmunity: An Intimate Relationship

Lina Petersone et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Review Pharmacology & Pharmacy

Drugs approved for the treatment of multiple sclerosis: review of their safety profile

Fabiana Auricchio et al.

EXPERT OPINION ON DRUG SAFETY (2017)

Add to Collection

Article Immunology

Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012-15

Tara Harris et al.

VACCINE (2017)

Add to Collection

Article Clinical Neurology

Quitting smoking: An early non-motor feature of Parkinson's disease?

Marcello Moccia et al.

PARKINSONISM & RELATED DISORDERS (2015)

Add to Collection

Review Clinical Neurology

Sex and gender issues in multiple sclerosis

Hanne F. Harbo et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2013)

Add to Collection

Review Pharmacology & Pharmacy

Pharmacovigilance in Italy: An overview

Carmela Mazzitello et al.

JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2013)

Add to Collection

Review Psychiatry

Epidemiology of multiple sclerosis in Europe: A Review

Ephrosyni Koutsouraki et al.

INTERNATIONAL REVIEW OF PSYCHIATRY (2010)

Add to Collection

Article Public, Environmental & Occupational Health

Monthly Ambient Sunlight, Infections and Relapse Rates in Multiple Sclerosis

Helen Tremlett et al.

NEUROEPIDEMIOLOGY (2008)

Add to Collection

Article Clinical Neurology

The risk of relapses in multiple sclerosis during systemic infections

Jorge Correale et al.

NEUROLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.